The estrogen receptor CpG island is methylated in most hematopoietic neoplasms

Jean Pierre J Issa, Barbara A. Zehnbauer, Curt I. Civin, Michael I. Collector, Saul J. Sharkis, Nancy E. Davidson, Scott H Kaufmann, Stephen B. Baylin

Research output: Contribution to journalArticle

138 Citations (Scopus)

Abstract

Estrogen appears to be a negative regulator of normal hematopoiesis. Chromosome 6q, which contains the estrogen receptor (ER) gene, is frequently altered in human hematopoietic neoplasms. The ER gene, which has growth and metastasis suppressor activity in many different cell types, is inactivated by promoter methylation in some ER-negative breast tumors and 100% of colorectal tumors. We now report that the promoter region of the ER gene is aberrantly methylated in 86% of human hematopoietic tumors, including 8 of 9 pediatric acute lymphocytic leukemia, 17 of 18 adult acute lymphocytic leukemia, 21 of 23 adult acute myelogenous leukemia, 3 of 6 chronic phase chronic myelogenous leukemia, 9 of 9 blast crisis chronic myelogenous leukemia and 5 of 8 lymphomas. This methylation event was also present in all nine leukemia cell lines examined, where it was associated with very low or absent ER expression. In addition, rat and mouse leukemia cell lines also exhibited this change, indicating that ER CpG island methylation in leukemias is conserved among species. Our results suggest that ER CpG island methylation could be an important step in the genesis of human hematopoietic neoplasms and might be a useful molecular marker for monitoring the clinical status of these diseases.

Original languageEnglish (US)
Pages (from-to)973-977
Number of pages5
JournalCancer Research
Volume56
Issue number5
StatePublished - Mar 1 1996

Fingerprint

CpG Islands
Hematologic Neoplasms
Estrogen Receptors
Methylation
Leukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Genes
Leukemia, Myeloid, Chronic Phase
Blast Crisis
Cell Line
Hematopoiesis
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Genetic Promoter Regions
Acute Myeloid Leukemia
Colorectal Neoplasms
Lymphoma
Estrogens
Chromosomes
Biomarkers
Pediatrics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Issa, J. P. J., Zehnbauer, B. A., Civin, C. I., Collector, M. I., Sharkis, S. J., Davidson, N. E., ... Baylin, S. B. (1996). The estrogen receptor CpG island is methylated in most hematopoietic neoplasms. Cancer Research, 56(5), 973-977.

The estrogen receptor CpG island is methylated in most hematopoietic neoplasms. / Issa, Jean Pierre J; Zehnbauer, Barbara A.; Civin, Curt I.; Collector, Michael I.; Sharkis, Saul J.; Davidson, Nancy E.; Kaufmann, Scott H; Baylin, Stephen B.

In: Cancer Research, Vol. 56, No. 5, 01.03.1996, p. 973-977.

Research output: Contribution to journalArticle

Issa, JPJ, Zehnbauer, BA, Civin, CI, Collector, MI, Sharkis, SJ, Davidson, NE, Kaufmann, SH & Baylin, SB 1996, 'The estrogen receptor CpG island is methylated in most hematopoietic neoplasms', Cancer Research, vol. 56, no. 5, pp. 973-977.
Issa JPJ, Zehnbauer BA, Civin CI, Collector MI, Sharkis SJ, Davidson NE et al. The estrogen receptor CpG island is methylated in most hematopoietic neoplasms. Cancer Research. 1996 Mar 1;56(5):973-977.
Issa, Jean Pierre J ; Zehnbauer, Barbara A. ; Civin, Curt I. ; Collector, Michael I. ; Sharkis, Saul J. ; Davidson, Nancy E. ; Kaufmann, Scott H ; Baylin, Stephen B. / The estrogen receptor CpG island is methylated in most hematopoietic neoplasms. In: Cancer Research. 1996 ; Vol. 56, No. 5. pp. 973-977.
@article{08f28d9b731244978c59d4c030f3003c,
title = "The estrogen receptor CpG island is methylated in most hematopoietic neoplasms",
abstract = "Estrogen appears to be a negative regulator of normal hematopoiesis. Chromosome 6q, which contains the estrogen receptor (ER) gene, is frequently altered in human hematopoietic neoplasms. The ER gene, which has growth and metastasis suppressor activity in many different cell types, is inactivated by promoter methylation in some ER-negative breast tumors and 100{\%} of colorectal tumors. We now report that the promoter region of the ER gene is aberrantly methylated in 86{\%} of human hematopoietic tumors, including 8 of 9 pediatric acute lymphocytic leukemia, 17 of 18 adult acute lymphocytic leukemia, 21 of 23 adult acute myelogenous leukemia, 3 of 6 chronic phase chronic myelogenous leukemia, 9 of 9 blast crisis chronic myelogenous leukemia and 5 of 8 lymphomas. This methylation event was also present in all nine leukemia cell lines examined, where it was associated with very low or absent ER expression. In addition, rat and mouse leukemia cell lines also exhibited this change, indicating that ER CpG island methylation in leukemias is conserved among species. Our results suggest that ER CpG island methylation could be an important step in the genesis of human hematopoietic neoplasms and might be a useful molecular marker for monitoring the clinical status of these diseases.",
author = "Issa, {Jean Pierre J} and Zehnbauer, {Barbara A.} and Civin, {Curt I.} and Collector, {Michael I.} and Sharkis, {Saul J.} and Davidson, {Nancy E.} and Kaufmann, {Scott H} and Baylin, {Stephen B.}",
year = "1996",
month = "3",
day = "1",
language = "English (US)",
volume = "56",
pages = "973--977",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - The estrogen receptor CpG island is methylated in most hematopoietic neoplasms

AU - Issa, Jean Pierre J

AU - Zehnbauer, Barbara A.

AU - Civin, Curt I.

AU - Collector, Michael I.

AU - Sharkis, Saul J.

AU - Davidson, Nancy E.

AU - Kaufmann, Scott H

AU - Baylin, Stephen B.

PY - 1996/3/1

Y1 - 1996/3/1

N2 - Estrogen appears to be a negative regulator of normal hematopoiesis. Chromosome 6q, which contains the estrogen receptor (ER) gene, is frequently altered in human hematopoietic neoplasms. The ER gene, which has growth and metastasis suppressor activity in many different cell types, is inactivated by promoter methylation in some ER-negative breast tumors and 100% of colorectal tumors. We now report that the promoter region of the ER gene is aberrantly methylated in 86% of human hematopoietic tumors, including 8 of 9 pediatric acute lymphocytic leukemia, 17 of 18 adult acute lymphocytic leukemia, 21 of 23 adult acute myelogenous leukemia, 3 of 6 chronic phase chronic myelogenous leukemia, 9 of 9 blast crisis chronic myelogenous leukemia and 5 of 8 lymphomas. This methylation event was also present in all nine leukemia cell lines examined, where it was associated with very low or absent ER expression. In addition, rat and mouse leukemia cell lines also exhibited this change, indicating that ER CpG island methylation in leukemias is conserved among species. Our results suggest that ER CpG island methylation could be an important step in the genesis of human hematopoietic neoplasms and might be a useful molecular marker for monitoring the clinical status of these diseases.

AB - Estrogen appears to be a negative regulator of normal hematopoiesis. Chromosome 6q, which contains the estrogen receptor (ER) gene, is frequently altered in human hematopoietic neoplasms. The ER gene, which has growth and metastasis suppressor activity in many different cell types, is inactivated by promoter methylation in some ER-negative breast tumors and 100% of colorectal tumors. We now report that the promoter region of the ER gene is aberrantly methylated in 86% of human hematopoietic tumors, including 8 of 9 pediatric acute lymphocytic leukemia, 17 of 18 adult acute lymphocytic leukemia, 21 of 23 adult acute myelogenous leukemia, 3 of 6 chronic phase chronic myelogenous leukemia, 9 of 9 blast crisis chronic myelogenous leukemia and 5 of 8 lymphomas. This methylation event was also present in all nine leukemia cell lines examined, where it was associated with very low or absent ER expression. In addition, rat and mouse leukemia cell lines also exhibited this change, indicating that ER CpG island methylation in leukemias is conserved among species. Our results suggest that ER CpG island methylation could be an important step in the genesis of human hematopoietic neoplasms and might be a useful molecular marker for monitoring the clinical status of these diseases.

UR - http://www.scopus.com/inward/record.url?scp=0030063853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030063853&partnerID=8YFLogxK

M3 - Article

C2 - 8640788

AN - SCOPUS:0030063853

VL - 56

SP - 973

EP - 977

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 5

ER -